



The Indonesian Journal of General Medicine

A Comprehensive Literature Review of Management and Quality of Life of Hepatocellular Carcinoma

¹ Erick Persson Jeffry, ¹ Charles Sanjaya Seikka

¹ Faculty of Medicine, Veterans National Development University, Special
Region of Jakarta, Indonesia

² Internal Medicine Consultant, Kebonjati General Hospital, Bandung City,
Indonesia


Correspondence : erick.persson86@gmail.com

Article History :

Received date : 2024/10/19
Revised date : 2024/11/25
Accepted date : 2024/12/08
Published date : 2025/01/08



Copyright: © 2024 by the
authors. Submitted for possible
open access publication under
the terms and conditions of the
Creative Commons Attribution
(BY NC) license
(<https://creativecommons.org/licenses/by-nc/4.0/>).



ABSTRACT

Background: The management of hepatocellular carcinoma (HCC) is a multifaceted challenge that significantly impacts patients' quality of life (QoL). The literature reveals a growing body of research dedicated to understanding the intricate relationship between HCC management and health-related quality of life (HRQoL), as evidenced by a series of systematic reviews and studies spanning over a decade. **Literature Review:** The systematic review conducted by (Fan, 2011) underscores that patients with HCC experience a notably poorer HRQoL compared to those with chronic liver disease and the general population. Further, the global survey by (Gill et al., 2018) highlights significant gaps in patient information at diagnosis, with a majority feeling inadequately informed. The exploration of advanced HCC treatment options by (Li et al., 2019) reveals that while curative therapies exist for early-stage HCC, patients often present with advanced disease, where treatment options are limited. The study by (Zhou & Fountzilas, 2019) further examines the impact of systemic therapies on QoL, revealing that side effects from anticancer agents can lead to treatment interruptions, thereby diminishing the overall efficacy of the treatment. This finding highlights the importance of ongoing research to manage drug toxicity and improve the QoL of patients undergoing systemic therapy. The systematic review by (Wohlleber et al., 2021) advocates for standardized HRQoL measures, emphasizing their importance in informing treatment strategies and enhancing patient care. The review also discusses various HRQoL instruments, underscoring the need for their integration into clinical practice to better capture the patient experience. In examining prognostic factors, (Minami et al., 2022) emphasizes the role of early detection and effective management of HCV in improving both survival rates and QoL. **Conclusion:** In conclusion, the literature collectively emphasizes the intricate interplay between HCC management and quality of life. There is a clear need for continued research and enhanced clinical practices that prioritize patient-centered care, effective communication, and the integration of psychosocial support to improve the overall QoL for individuals living with HCC.

Keyword: Management, Quality of Life, Hepatocellular Carcinoma

INTRODUCTION

The management of hepatocellular carcinoma (HCC) is a multifaceted challenge that significantly impacts patients' quality of life (QoL). The literature reveals a growing body of research dedicated to understanding the intricate relationship between HCC management and health-related quality of life (HRQoL), as evidenced by a series of systematic reviews and studies spanning over a decade.

In 2011, (Fan, 2011) conducted a systematic review that aimed to identify various measures of HRQoL in patients with HCC, comparing their quality of life with that of individuals suffering from chronic liver disease and the general population. The findings indicated that HCC patients experienced worse physical, emotional, and functional HRQoL, while their social/family HRQoL appeared relatively better. The review highlighted the significance of treatment modalities, such as liver surgery and radiotherapy, in improving HRQoL, as well as the detrimental effects of symptoms like pain and fatigue.

Building on this foundation, a global survey conducted by (Gill et al., 2018) sought to elucidate the HCC patient journey across 13 countries. The results revealed a concerning gap in patient information at diagnosis, with 68% of respondents feeling inadequately informed. The survey also demonstrated that treatments such as sorafenib and TACE were associated with impaired QoL, underscoring the need for effective communication and supportive care throughout the treatment process.

(Li et al., 2019) further explored the treatment landscape for advanced HCC, emphasizing the importance of a multidisciplinary approach to treatment decision-making. The authors noted that while curative therapies exist for early-stage HCC, a significant proportion of patients present with advanced disease, where treatment options are limited and survival rates remain low. This study highlighted the psychological burden experienced by HCC patients, with feelings of fear and anxiety significantly affecting their QoL.

In the same year, (Zhou & Fountzilias, 2019) examined the impact of systemic therapy on QoL in advanced HCC patients, noting that side effects from anticancer agents could lead to treatment interruptions and reduced efficacy. Their findings emphasized the necessity for ongoing research into managing drug toxicity and enhancing the QoL of patients undergoing systemic therapy.

A systematic review by (Wohlleber et al., 2021) assessed the methodological properties of HRQoL instruments specific to primary liver cancer. The study underscored the importance of patient-reported outcomes in oncology, advocating for the use of standardized HRQoL measures to better inform treatment strategies and improve patient care.

(Minami et al., 2022) focused on prognostic factors influencing survival in HCV-related HCC patients undergoing molecular targeted therapies. Their research highlighted the advancements in treatment options and the critical role of early detection, which positively affect both survival and QoL. However, the authors cautioned that

while viral eradication is essential, other prognostic factors also warrant attention to enhance patient outcomes.

Most recently, (Seth et al., 2024) conducted a systematic review of clinical practice guidelines for HCC management, emphasizing the necessity of evidence-based approaches in treating patients at various stages of the disease. Their findings reiterated the significance of comprehensive management plans that address the diverse risk factors associated with HCC, ultimately aiming to improve survival rates and QoL.

Collectively, these studies illuminate the complex interplay between HCC management and quality of life, highlighting the critical need for continued research and enhanced clinical practices to support patients throughout their journey with this challenging disease.

LITERATURE REVIEW

The article titled "Health-Related Quality of Life and Adjustment in Patients with Hepatocellular Carcinoma" by (Fan, 2011) presents a systematic review

aimed at exploring various dimensions of health-related quality of life (HRQOL) among patients diagnosed with hepatocellular carcinoma (HCC). The review synthesizes findings from thirty-six articles, providing a comprehensive overview of how HCC affects patients' quality of life in comparison to those with chronic liver disease and the general population.

One of the critical insights from the article is the identification of disease-specific concerns that significantly impact HRQOL, such as pain, fatigue, nausea, jaundice, weight loss, and body image issues. These factors are paramount in understanding the multifaceted nature of HCC and its treatment implications. The findings indicate that patients with HCC experience notably worse physical, emotional, and functional HRQOL when juxtaposed with the general population, highlighting the severe burden of the disease. Interestingly, the review notes that social and family HRQOL tends to be better among HCC patients, suggesting that familial support may play a vital role

in mitigating some adverse effects of the disease.

The article further delves into the positive effects of various treatment modalities on HRQOL. Surgical interventions, hepatic artery transcatheter treatments, and radiotherapy are reported to enhance HRQOL, emphasizing the importance of effective management strategies in improving patient outcomes. The correlation between better liver function, early-stage disease, and absence of recurrence with improved HRQOL underscores the significance of early detection and intervention in HCC management.

Moreover, the review highlights the intricate relationships between psychological variables and HRQOL. It reveals that depression, uncertainty, and a chance health locus of control negatively impact HRQOL, while satisfaction with medical services is positively correlated with it. This indicates that addressing psychological well-being is crucial for enhancing HRQOL in HCC patients, suggesting that psychosocial interventions could be beneficial in

alleviating negative emotions and improving overall quality of life.

The article "Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey" by (Gill et al., 2018) presents a comprehensive examination of the patient experience among individuals diagnosed with hepatocellular carcinoma (HCC). The authors conducted a survey involving 256 patients across 13 countries, aiming to elucidate the challenges faced by HCC patients and their perceptions of the quality of life (QoL) throughout their treatment journey.

A significant finding from the survey is that a substantial majority, specifically 68% of respondents, felt inadequately informed about their condition at the time of diagnosis. This lack of information is critical, as it can adversely affect a patient's ability to make informed decisions regarding their treatment options and can contribute to feelings of anxiety and uncertainty about their health. The treatments explored in the study included oral anticancer therapy, transarterial chemoembolization

(TACE), and selective internal radiation therapy (SIRT), with varying implications for patients' QoL.

The results indicate that the majority of patients receiving sorafenib (81%), SIRT (45%), and TACE (32%) reported impaired QoL. This highlights a pressing concern regarding the side effects and overall impact of these treatments on patients' daily lives. The survey further revealed that only 0% of patients on sorafenib rated their QoL as 'excellent,' in stark contrast to the 42% who rated it as 'poor.' In comparison, patients undergoing SIRT and TACE also reported significant QoL challenges, with only a small percentage rating their experience positively.

The article also contextualizes the prevalence of HCC, noting it as the most common primary liver malignancy and a major contributor to cancer-related mortality worldwide. The geographical disparities in incidence rates underscore the complexity of managing HCC, as treatment success is intricately linked to accurate staging of the disease and

the extent of liver dysfunction. This aspect is particularly relevant for treatment strategies, as patients with very early or early-stage disease may benefit from curative interventions, while those with intermediate-stage disease typically receive TACE.

The article "Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life" by (Li et al., 2019) provides a comprehensive overview of the treatment options available for advanced hepatocellular carcinoma (HCC) and highlights the significant implications these treatments have on patients' quality of life (QoL). The authors adeptly situate HCC within the broader context of liver cancer, noting its prevalence as the fifth most common cancer and the second leading cause of cancer mortality worldwide. This contextualization emphasizes the urgency of addressing management strategies for HCC, particularly given that the disease is often diagnosed at advanced stages, where treatment options become limited.

The article identifies key risk factors associated with HCC, primarily cirrhosis due to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV), which account for a substantial proportion of cases. The authors effectively outline additional risk factors such as aflatoxins, excess alcohol consumption, diabetes, and nonalcoholic fatty liver disease, providing a thorough understanding of the multifaceted nature of HCC etiology. The geographical distribution of HCC incidence is also discussed, with higher rates observed in regions endemic to HBV, thereby underscoring the need for targeted public health interventions in these areas.

A critical aspect of the article is its examination of the treatment landscape for advanced HCC, particularly the Barcelona Clinic Liver Cancer (BCLC) staging system. This system is pivotal in guiding treatment decisions based on tumor burden and liver function. The authors provide a clear delineation of the treatment modalities available for various stages of HCC, including curative options for early-stage disease and the reliance on tyrosine

kinase inhibitors (TKIs) such as sorafenib and lenvatinib for advanced cases. However, the article notes a significant gap in the literature regarding the impact of these treatments on health-related quality of life (HRQoL), which is crucial for understanding the holistic effects of cancer management.

The authors emphasize that QoL is a vital consideration for HCC patients, who often experience heightened levels of fear, worry, and anxiety due to the poor prognosis associated with advanced stages of the disease. This underscores the necessity for future research to focus not only on survival outcomes but also on the psychosocial dimensions of living with HCC. The call for more comprehensive studies evaluating the HRQoL implications of new treatment modalities is particularly relevant, as it highlights the need for a patient-centered approach in cancer care.

The article "Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma" by (Zhou & Fountzilas, 2019) provides a thorough

examination of how systemic therapies, specifically sorafenib and regorafenib, affect the quality of life (QoL) of patients with advanced hepatocellular carcinoma (HCC). The authors highlight a critical issue in oncology: the side effects of anticancer agents, which can lead to treatment interruptions and dose reductions. This phenomenon is particularly concerning in the context of advanced HCC, where maintaining optimal therapeutic efficacy is paramount.

(Zhou & Fountzilas, 2019) emphasize that the QoL measures observed with these treatments did not show significant improvement, suggesting that the current systemic therapies may not be as effective in enhancing patient well-being as hoped. This finding raises important questions about the balance between the potential benefits of aggressive treatment and the adverse effects that can detract from a patient's overall quality of life.

The authors advocate for further research aimed at identifying cost-effective pharmaceutical agents and developing optimal intervention

protocols that can mitigate drug toxicity while managing underlying conditions such as cirrhosis. This is vital for tailoring treatment plans that align more closely with the individual needs of patients. The multidisciplinary tumor board format currently employed in treatment planning is commendable; however, (Zhou & Fountzilas, 2019) propose that integrating ancillary specialties could enhance the management of medication side effects and ultimately improve QoL outcomes.

The article "Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies" by (Wohlleber et al., 2021) provides a comprehensive examination of health-related quality of life (HRQoL) as a critical outcome parameter in the management of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA). The authors emphasize the importance of patient-reported outcomes (PROs) in oncology, defining them as outcomes evaluated directly by patients based on their

perceptions of their disease and treatments. This perspective is particularly relevant in the context of HCC and CCA, where the burden of disease and treatment can significantly impact patients' quality of life.

The systematic review identifies various HRQoL measurement tools, categorizing them into generic, cancer-specific, cancer-type-specific, and utility-based instruments. This classification is crucial as it allows for a nuanced understanding of how different instruments can capture the multifaceted nature of HRQoL, which is especially important given the complex treatment landscape for liver cancers. The authors note that the prognosis for patients with HCC and CCA remains poor, with a dismal 5-year overall survival rate, highlighting the urgent need for effective management strategies that prioritize patients' quality of life alongside traditional clinical outcomes.

One of the key contributions of this article is its meta-analysis, which synthesizes quantitative data to

compare the HRQoL outcomes associated with different treatment modalities, including surgical resection, interventional treatments such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE), and systemic therapies. By providing a comparative analysis of these strategies, the authors offer valuable insights into the potential trade-offs between treatment efficacy and quality of life, which is essential for informed decision-making in clinical practice.

However, while the article presents a thorough evaluation of HRQoL instruments and their application in the context of liver cancer, it is important to critically assess the methodological quality of the studies included in the review. The authors acknowledge the variability in the instruments used and the potential biases that may arise from different study designs. Furthermore, the article could benefit from a more in-depth discussion on how these HRQoL measures can be integrated into routine clinical practice to enhance patient-centered care.

The article "Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response" by (Minami et al., 2022) provides a comprehensive analysis of the complex interplay between hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC), emphasizing the significance of prognostic factors in the management of HCC patients.

HCC, as noted in the article, is a predominant form of primary liver cancer, contributing significantly to cancer-related mortality. The authors assert that chronic HCV infection is a major risk factor for the development of HCC, primarily due to the resultant chronic inflammation and cellular damage. This relationship underscores the importance of effective management strategies targeting both HCV and HCC to improve patient outcomes.

The article critically evaluates various treatment modalities available for HCC, including locoregional therapies such as surgical resection, thermal ablation, and transcatheter

arterial chemoembolization. These interventions have been shown to enhance survival rates, particularly when administered at earlier stages of cancer. Additionally, the emergence of systemic therapies, including chemotherapy and immune-checkpoint inhibitors, has extended survival in a significant proportion of advanced HCC patients. The authors highlight a survival benefit in 50-60% of these patients, which marks a notable advancement in treatment efficacy.

The discussion on cirrhosis and its complications, such as esophageal varices and ascites, is particularly relevant to the quality of life of HCC patients. The article emphasizes that managing these complications, especially ascites, can lead to substantial improvements in patient well-being. This aspect of care is critical, as quality of life is an essential consideration in the treatment of chronic diseases like HCC.

Moreover, the article points out the remarkable progress in HCV treatments, particularly the advent of direct-acting antivirals, which have

achieved sustained virological response rates exceeding 95%. The authors argue that viral eradication is crucial not only for halting disease progression but also for minimizing morbidity associated with HCC. This perspective aligns with the notion that addressing the underlying viral infection can have direct implications on the prognosis and management of HCC.

However, the authors also acknowledge that despite advancements in treatment, survival issues remain unresolved, necessitating further investigation into additional prognostic factors. This critical evaluation highlights the need for a multifaceted approach to patient management that goes beyond viral eradication, considering the broader spectrum of factors influencing survival.

The article titled "Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review" by (Seth et al., 2024) provides a comprehensive examination of current clinical practice guidelines (CPGs) for managing hepatocellular

carcinoma (HCC). The authors conducted a systematic review following the PRISMA guidelines, ensuring a rigorous methodology in selecting relevant studies from various databases such as MEDLINE, Embase, and Cochrane Library. This approach not only strengthens the validity of their findings but also highlights the importance of evidence-based management in clinical settings.

The review encompasses studies involving HCC patients across different stages, from initial surveillance to peri-operative management, thereby offering a broad perspective on the disease's management. The inclusion criteria focused on peer-reviewed English language articles published between 2005 and 2022, which enhances the relevance and timeliness of the guidelines discussed. One of the critical insights presented is the identification of various risk factors associated with HCC, including cirrhosis, hepatitis B and C viruses, alcohol consumption, and metabolic disorders such as non-alcoholic fatty liver disease (NAFLD). This comprehensive identification of risk

factors is crucial for clinicians as it aids in early detection and preventive strategies.

The article emphasizes the significance of staging in the management of HCC, noting that accurate staging is essential for predicting patient survival and determining appropriate treatment options. This aspect aligns with contemporary practices in oncology, where personalized treatment plans are increasingly prioritized. The authors effectively underscore that understanding the staging of HCC can impact the quality of life for patients, as it directly influences treatment decisions and subsequent outcomes.

However, while the review provides an extensive overview of the CPGs, it could benefit from a deeper exploration of how these guidelines are implemented in clinical practice and their actual impact on patient outcomes and quality of life. The translation of guidelines into practice often encounters barriers such as clinician adherence, patient compliance, and healthcare resource availability, which are critical factors that could be discussed to provide a

more holistic view of HCC management.

CONCLUSION

The management of hepatocellular carcinoma (HCC) presents a complex challenge that significantly impacts patients' quality of life (QoL). The literature reveals a multifaceted relationship between HCC management and health-related quality of life (HRQoL), with various studies highlighting the importance of treatment modalities and patient experiences throughout their treatment journey.

The systematic review conducted by (Fan, 2011) underscores that patients with HCC experience a notably poorer HRQoL compared to those with chronic liver disease and the general population. The study identifies specific disease-related concerns, such as pain and fatigue, that contribute to this decline in QoL, while also noting that social and family support can mitigate some negative effects. Treatment modalities, including surgical interventions and radiotherapy, have been shown to enhance HRQoL,

particularly when initiated early in the disease process.

Further, the global survey by (Gill et al., 2018) highlights significant gaps in patient information at diagnosis, with a majority feeling inadequately informed. This lack of information correlates with impaired QoL, particularly among those receiving treatments like sorafenib and TACE, which are associated with significant side effects. The need for effective communication and supportive care is emphasized as crucial for improving patient experiences.

The exploration of advanced HCC treatment options by (Li et al., 2019) reveals that while curative therapies exist for early-stage HCC, patients often present with advanced disease, where treatment options are limited. The psychological burden, including fear and anxiety, is noted to adversely affect QoL, indicating the necessity for a multidisciplinary approach to treatment that considers both physical and psychological well-being.

The study by (Zhou & Fountzilias, 2019) further examines

the impact of systemic therapies on QoL, revealing that side effects from anticancer agents can lead to treatment interruptions, thereby diminishing the overall efficacy of the treatment. This finding highlights the importance of ongoing research to manage drug toxicity and improve the QoL of patients undergoing systemic therapy.

The systematic review by (Wohlleber et al., 2021) advocates for standardized HRQoL measures, emphasizing their importance in informing treatment strategies and enhancing patient care. The review also discusses various HRQoL instruments, underscoring the need for their integration into clinical practice to better capture the patient experience.

In examining prognostic factors, (Minami et al., 2022) emphasizes the role of early detection and effective management of HCV in improving both survival rates and QoL. The authors argue that while viral eradication is crucial, attention must also be given to other factors that influence patient outcomes.

Lastly, the systematic review of clinical practice guidelines by (Seth et al., 2024) stresses the need for evidence-based approaches in HCC management. The review highlights the significance of accurate staging and the identification of risk factors, which can guide treatment decisions and ultimately affect patient QoL.

In conclusion, the literature collectively emphasizes the intricate interplay between HCC management and quality of life. There is a clear need for continued research and enhanced clinical practices that prioritize patient-centered care, effective communication, and the integration of psychosocial support to improve the overall QoL for individuals living with HCC.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content

for journal submission and publication

REFERENCES

1. Fan, S. Y., 2011. Health-Related Quality of Life and Adjustment in Patients with Hepatocellular Carcinoma. [PDF]
2. Gill, J., Baiceanu, A., J Clark, P., Langford, A., Latiff, J., Yang, P. M., M Yoshida, E., & Kanavos, P., 2018. Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. [PDF]
3. Li, D., Sedano, S., Allen, R., Gong, J., Cho, M., & Sharma, S., 2019. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. ncbi.nlm.nih.gov
4. Zhou, K. & Fountzilas, C., 2019. Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. ncbi.nlm.nih.gov
5. Wohlleber, K., Heger, P., Probst, P., Engel, C., K. Diener, M., & L. Mihaljevic, A., 2021. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies. ncbi.nlm.nih.gov
6. Minami, Y., Aoki, T., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Ueshima, K., Nishida, N., & Kudo, M., 2022. Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response. ncbi.nlm.nih.gov
7. Seth, I., Siu, A., Hewitt, L., Budak, U., Farah, B., & Jaber, M., 2024. Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review. ncbi.nlm.nih.gov